2015 Global Survey on Liquid Biopsy Adoption Trends

2015 Global Survey on Liquid Biopsy Adoption Trends

Learn the Promising Technologies and Bottlenecks for CTCs and ctDNA—A Voice of Customer Study

RELEASE DATE
04-Nov-2015
REGION
North America
Research Code: 9AB9-00-2F-00-00
SKU: LS00164-NA-MR_17148

$6,950.00

Special Price $5,212.50 save 25 %

In stock
SKU
LS00164-NA-MR_17148

$6,950.00

$5,212.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The primary goal of this research is to analyze the current and future adoption patterns on the usage of liquid biopsy. Key information the survey seeks to collect include the following:
•     Current and future use of liquid biopsy by organization type
•     Timeframe of liquid biopsy adoption amidst future users
•     Predominantly used cell types—CTCs, ctDNA, cfDNA and Evs—by organization type
•     Sample inflow to conduct liquid biopsy tests
•     Preference for sample types: blood, saliva, stool, serum, and so on.
•     Correlation analysis of sample type and biomarker type
•     Promising applications for liquid biopsy—current and future
•     Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on
•     Technologies used to detect CtDNA—current vs. future users
•     Technologies used to detect CTCs
•     Vendor popularity for specific biomarkers and reimbursement scenario
•     Bottlenecks to mainstream implementation of liquid biopsy

Table of Contents

Research Objectives

Research Methodology

Research Methodology (continued)

Respondent Demographics

Respondent Demographics (continued)

Respondent Demographics—Current and Future Users

Key Findings

Top 7 Brands for Liquid Biopsy

Overall Use of Liquid Biopsy by Organization Type

Timeframe for Future Adoption

Timeframe for Adoption by Organization Type

Opinion on Use of Liquid Biopsy as an Adjunct to Tissue Biopsy

Liquid Biopsy as an Adjunct to Tissue Biopsy (continued)

Overall Biomarker Usage

Overall Biomarker Usage—Hospital Laboratories

Overall Biomarker Usage—Pharmaceutical and Diagnostic Companies

Overall Biomarker Usage—Reference Laboratories*

Overall Biomarker Usage—Research Institutes and Universities

Sample Volume Per Month

Sample Format—Overall

Sample Format—Current Users vs. Future Users

Sample Format by Organization Type

Technologies Used to Detect ctDNA—Overview

Technologies Used to Detect ctDNA—Current and Future User Trends

Technologies Used to Detect ctDNA by Organization Type

Technologies Used to Detect CTC—Overview

Technologies Used to Detect CTC—Current and Future User Trends

Technologies Used to Detect CTC by Organization Type

Brand Familiarity for Tumor Profiling

Promising Applications of Liquid Biopsy (Overall)

Promising Applications by Organization Type

Promising Applications—Current and Future Users

Bottlenecks in Liquid Biopsy

Bottlenecks by Biomarker Type

Liquid Biopsy Usage to Profile Types

Tumor Profiling by Organization Type

Liquid Biopsy Approaches—Current vs. Future Users

Liquid Biopsy Approach by Organization Type

Correlation of Sample Type and Liquid Biopsy Approach

CTC-Specific Liquid Biopsy Approaches—Current vs. Future Users

ctDNA-Specific Liquid Biopsy Approaches—Current vs. Future Users

Germline or cfDNA-Specific Liquid Biopsy Approaches—Current vs. Future Users

EVs-Specific Liquid Biopsy Approaches—Current vs. Future Users

Overall Brand Perception

Brand Perception Organization Type

Top 7 Current and Future Brand Perception

Brand Preference by Biomarker Type—CTCs

Brand Preference by Biomarker Type—CtDNA

Brand Preference by Biomarker Type—Germline and cfDNA

Brand Preference by Biomarker Type—Evs

Reimbursement Trends (Overall)

Reimbursement Trend by Organization Type

Reimbursement by Technology—ctDNA

Reimbursement by Technology—CTC

Mutant Allele Detection Limit—Diagnosis and Monitoring

Reasons for Choosing Blood Over Other Sample Types

Reasons for Choosing Blood Over Other Sample Types (continued)

Reasons for Choosing Blood Over Other Sample Types (continued)

Reasons for Choosing Blood Over Other Sample Types (continued)

Reasons for Choosing Blood Over Other Sample Types (continued)

Legal Disclaimer

Additional Sources of Information

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

North America and Europe Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The primary goal of this research is to analyze the current and future adoption patterns on the usage of liquid biopsy. Key information the survey seeks to collect include the following: • Current and future use of liquid biopsy by organization type • Timeframe of liquid biopsy adoption amidst future users • Predominantly used cell types—CTCs, ctDNA, cfDNA and Evs—by organization type • Sample inflow to conduct liquid biopsy tests • Preference for sample types: blood, saliva, stool, serum, and so on. • Correlation analysis of sample type and biomarker type • Promising applications for liquid biopsy—current and future • Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on • Technologies used to detect CtDNA—current vs. future users • Technologies used to detect CTCs • Vendor popularity for specific biomarkers and reimbursement scenario • Bottlenecks to mainstream implementation of liquid biopsy
More Information
No Index No
Podcast No
Author Divyaa Ravishankar
WIP Number 9AB9-00-2F-00-00
Is Prebook No